bioMérieux S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pierre Boulud
- Full Time Employees
- 14,147
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 376 Chemin De l’Orme Marcy l'Étoile France 69280
- IPO Date
- Sep 21, 2017
- Website
- biomerieux.com
- Similar Companies
- Business
- bioMérieux S.A. (Ticker: BMXMF) develops, manufactures and markets in vitro diagnostic (IVD) solutions for medical and industrial applications worldwide. The company offers a broad portfolio of diagnostic systems, reagents and software; including molecular biology tests such as BioFire® multiplex PCR panels for infectious disease detection, immunoassay systems like VIDAS® for antigen/antibody assays, microbiology automation platforms including PREVI® Isola and VITEK® 2 for microbial identification and susceptibility testing, and quality control products under the API® and BioBall® brands. It serves clinical laboratories, hospitals, blood banks, pharmaceutical and food industries with solutions focused on infectious diseases, oncology, cardiovascular conditions, sepsis management, and industrial testing for contaminants in food, water and pharmaceuticals; operating in over 150 countries with manufacturing sites in Europe, North America and Asia. Founded in 1963 and headquartered in Marcy l'Etoile, near Lyon, France, bioMérieux operates through subsidiaries like BioFire Diagnostics in the US and focuses on key segments including clinical diagnostics (80% of sales), industrial applications and innovative technologies like syndromic testing and artificial intelligence integration. In the last two years, bioMérieux expanded its offerings through the launch of new BioFire® panels for respiratory and gastrointestinal pathogens amid heightened demand post-COVID, formed strategic partnerships with health authorities for antimicrobial resistance surveillance, and completed acquisitions to strengthen molecular diagnostics capabilities; additionally, the company announced a major reorganization in late 2024 to streamline its industrial division and enhance digital health services integration.
bioMérieux S.A. (BMXXY) Q1 2026 Sales/Trading Call Transcript
Analyzing HealthEquity (NASDAQ:HQY) and bioMerieux (OTCMKTS:BMXMF)
bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Time to Buy?
bioMérieux S.A. (BMXXY) Q4 2025 Earnings Call Transcript
bioMerieux (OTCMKTS:BMXMF) Sees Unusually-High Trading Volume – Time to Buy?
bioMérieux S.A. (BMXXY) Analyst/Investor Day Transcript
bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript
bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript
bioMérieux: Pioneering In Vitro Diagnostics
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript
4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis